m+Medelevator.RU
← Поиск публикаций
Fundamental & clinical pharmacology · 2020

Amiodarone and Parkinsonism: a pharmacovigilance study.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Montastruc Jean-Louis, Durrieu Geneviève

Аннотация

BACKGROUND: Some case reports have described parkinsonism with amiodarone. We investigated a putative association between parkinsonism and exposure to amiodarone.

METHODS: We used the WHO pharmacovigilance database (VigiBase® ). All adverse drug reactions with 'Parkinson-like events' and amiodarone were included. Four disproportionality analyses were performed: 1/after inclusion of all reports, 2/according to sex, 3/for the twenty last years (2000-2019), and 4/after exclusion of concomitant drugs known to induce parkinsonism (antipsychotic, antivertigo, antiemetic antinauseant drugs, flunarizine). Results are expressed as reporting odds ratios (ROR; 95% CI) and information component (IC).

RESULTS: No significant association was found in the whole population [ROR = 0.83 (0.65-1.06), IC = -0.7 (IC025  = -0.65)], in men, in women, for the 2000-2019 years, or after exclusion of drugs inducing parkinsonism.

CONCLUSION: We failed to find any signal of parkinsonism with amiodarone. We suggest that reports of parkinsonism with amiodarone could be mainly explained by other underlying causes.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты